Show simple item record

dc.contributor.authorO'Shea, Eileen F.*
dc.contributor.authorCotter, Paul D.*
dc.contributor.authorStanton, Catherine*
dc.contributor.authorRoss, R Paul*
dc.contributor.authorHill, Colin*
dc.date.accessioned2012-08-20T11:42:43Z
dc.date.available2012-08-20T11:42:43Z
dc.date.issued16/01/2012
dc.identifier.citationEileen F. O'Shea, Paul D. Cotter, Catherine Stanton, R. Paul Ross, Colin Hill. Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: Bacteriocins and conjugated linoleic acid. International Journal of Food Microbiology, 152(3), 16 January 2012, 189-205: DOI 10.1016/j.ijfoodmicro.2011.05.025.en_GB
dc.identifier.issn0168-1605
dc.identifier.urihttp://hdl.handle.net/11019/85
dc.descriptionpeer-revieweden_GB
dc.description.abstractThe mechanisms by which intestinal bacteria achieve their associated health benefits can be complex and multifaceted. In this respect, the diverse microbial composition of the human gastrointestinal tract (GIT) provides an almost unlimited potential source of bioactive substances (pharmabiotics) which can directly or indirectly affect human health. Bacteriocins and fatty acids are just two examples of pharmabiotic substances which may contribute to probiotic functionality within the mammalian GIT. Bacteriocin production is believed to confer producing strains with a competitive advantage within complex microbial environments as a consequence of their associated antimicrobial activity. This has the potential to enable the establishment and prevalence of producing strains as well as directly inhibiting pathogens within the GIT. Consequently, these antimicrobial peptides and the associated intestinal producing strains may be exploited to beneficially influence microbial populations. Intestinal bacteria are also known to produce a diverse array of health-promoting fatty acids. Indeed, certain strains of intestinal bifidobacteria have been shown to produce conjugated linoleic acid (CLA), a fatty acid which has been associated with a variety of systemic health-promoting effects. Recently, the ability to modulate the fatty acid composition of the liver and adipose tissue of the host upon oral administration of CLA-producing bifidobacteria and lactobacilli was demonstrated in a murine model. Importantly, this implies a potential therapeutic role for probiotics in the treatment of certain metabolic and immunoinflammatory disorders. Such examples serve to highlight the potential contribution of pharmabiotic production to probiotic functionality in relation to human health maintenance.en_GB
dc.description.sponsorshipThis work was funded by Food Institutional Research Measure of the Department of Agriculture, Fisheries and Food (grant no. 04R & DC), and the Alimentary Pharmabiotic Centre (which is funded by the Science Foundation of Ireland (SFI), through the Irish Government's National Development Plan). The authors and their work were supported by SFI (grant no. 07/CE/B1368).en_GB
dc.language.isoenen_GB
dc.publisherElsevier Science B.V.en_GB
dc.relation.ispartofseriesInternational Journal of Food Microbiology;vol 152
dc.subjectGastrointestinal tract (GIT)en_GB
dc.subjectPharmabioticen_GB
dc.subjectBacteriocinen_GB
dc.subjectConjugated linoleic acid (CLA)en_GB
dc.titleProduction of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: Bacteriocins and conjugated linoleic aciden_GB
dc.typeArticleen_GB
dc.identifier.rmis5271
dc.identifier.doihttp://dx.doi.org/10.1016/j.ijfoodmicro.2011.05.025
dc.contributor.sponsorDepartment of Agriculture, Food and the Marine, Ireland
dc.contributor.sponsorScience Foundation Ireland
dc.contributor.sponsorGrantNumber04R & DC
dc.contributor.sponsorGrantNumber07/CE/B1368
refterms.dateFOA2018-01-12T07:25:53Z


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
O'Shea et al Review 2012 post ...
Size:
356.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record